AR083095A1 - Cocristal de aprepitant l-prolina y composicion farmaceutica - Google Patents
Cocristal de aprepitant l-prolina y composicion farmaceuticaInfo
- Publication number
- AR083095A1 AR083095A1 ARP110103486A AR083095A1 AR 083095 A1 AR083095 A1 AR 083095A1 AR P110103486 A ARP110103486 A AR P110103486A AR 083095 A1 AR083095 A1 AR 083095A1
- Authority
- AR
- Argentina
- Prior art keywords
- proline
- aprepitant
- crystal
- prolina
- pharmaceutical composition
- Prior art date
Links
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 title abstract 3
- 229960001372 aprepitant Drugs 0.000 title abstract 3
- 239000013078 crystal Substances 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 229960002429 proline Drugs 0.000 abstract 5
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract 3
- 229930182821 L-proline Natural products 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010012335 Dependence Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000007803 itching Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000017520 skin disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38574410P | 2010-09-23 | 2010-09-23 | |
| US201161439654P | 2011-02-04 | 2011-02-04 | |
| US201161498214P | 2011-06-17 | 2011-06-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR083095A1 true AR083095A1 (es) | 2013-01-30 |
Family
ID=44907915
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110103486 AR083095A1 (es) | 2010-09-23 | 2011-09-23 | Cocristal de aprepitant l-prolina y composicion farmaceutica |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9029369B2 (enExample) |
| EP (1) | EP2618828B1 (enExample) |
| JP (1) | JP5997162B2 (enExample) |
| KR (1) | KR101833578B1 (enExample) |
| CN (1) | CN103221049B (enExample) |
| AR (1) | AR083095A1 (enExample) |
| AU (1) | AU2011306391B2 (enExample) |
| BR (1) | BR112013006651A2 (enExample) |
| CA (1) | CA2846460C (enExample) |
| ES (1) | ES2616752T3 (enExample) |
| IL (1) | IL225443A0 (enExample) |
| TW (1) | TWI540131B (enExample) |
| WO (1) | WO2012038937A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103221049B (zh) | 2010-09-23 | 2015-11-25 | 诺弗米克斯有限公司 | 阿瑞匹坦l-脯氨酸组合物和共晶 |
| WO2013076659A1 (en) | 2011-11-25 | 2013-05-30 | Nuformix Limited | Aprepitant l-proline solvates - compositions and cocrystals |
| US10098859B2 (en) | 2012-09-05 | 2018-10-16 | Amri Ssci, Llc | Cocrystals of p-coumaric acid |
| US20160324881A1 (en) * | 2013-12-30 | 2016-11-10 | Oncoprevent Gmbh | Neurokinin-1 Receptor Antagonists For Use In A Method Of Prevention Of Cancer |
| SG11202007530XA (en) * | 2018-02-07 | 2020-09-29 | Reata Pharmaceuticals Inc | Co-crystal forms of a novobiocin analog and proline |
| CN116283947A (zh) * | 2023-02-07 | 2023-06-23 | 成都医学院 | 一种阿瑞匹坦共晶及其制备方法和用途 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US6048859A (en) | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| IL111960A (en) | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| ZA985765B (en) | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| CA2489984A1 (en) * | 2002-06-21 | 2003-12-31 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
| JP4923182B2 (ja) * | 2003-02-28 | 2012-04-25 | マクニール−ピーピーシー・インコーポレーテツド | セレコキシブ及びニコチンアミド共結晶並びにこの共結晶を含む医薬組成物 |
| EP2034952A4 (en) * | 2006-06-16 | 2011-08-17 | Reddys Lab Ltd Dr | APREPITANT COMPOSITIONS |
| US20110009362A1 (en) * | 2008-02-27 | 2011-01-13 | Dr. Reddy's Laboratories Ltd. | Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof |
| CN103221049B (zh) | 2010-09-23 | 2015-11-25 | 诺弗米克斯有限公司 | 阿瑞匹坦l-脯氨酸组合物和共晶 |
-
2011
- 2011-09-23 CN CN201180055997.5A patent/CN103221049B/zh active Active
- 2011-09-23 JP JP2013529758A patent/JP5997162B2/ja active Active
- 2011-09-23 KR KR1020137010228A patent/KR101833578B1/ko active Active
- 2011-09-23 US US13/825,380 patent/US9029369B2/en active Active
- 2011-09-23 ES ES11779217.6T patent/ES2616752T3/es active Active
- 2011-09-23 CA CA2846460A patent/CA2846460C/en active Active
- 2011-09-23 AR ARP110103486 patent/AR083095A1/es unknown
- 2011-09-23 AU AU2011306391A patent/AU2011306391B2/en active Active
- 2011-09-23 WO PCT/IB2011/054210 patent/WO2012038937A1/en not_active Ceased
- 2011-09-23 BR BR112013006651A patent/BR112013006651A2/pt not_active Application Discontinuation
- 2011-09-23 EP EP11779217.6A patent/EP2618828B1/en active Active
- 2011-09-23 TW TW100134362A patent/TWI540131B/zh active
-
2013
- 2013-03-21 IL IL225443A patent/IL225443A0/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012038937A1 (en) | 2012-03-29 |
| TW201217366A (en) | 2012-05-01 |
| EP2618828A1 (en) | 2013-07-31 |
| TWI540131B (zh) | 2016-07-01 |
| KR101833578B1 (ko) | 2018-02-28 |
| AU2011306391B2 (en) | 2016-12-15 |
| KR20140040671A (ko) | 2014-04-03 |
| JP2013537901A (ja) | 2013-10-07 |
| CA2846460C (en) | 2019-01-08 |
| CN103221049B (zh) | 2015-11-25 |
| BR112013006651A2 (pt) | 2017-07-18 |
| CA2846460A1 (en) | 2012-03-29 |
| IL225443A0 (en) | 2013-06-27 |
| US20130252949A1 (en) | 2013-09-26 |
| JP5997162B2 (ja) | 2016-09-28 |
| EP2618828B1 (en) | 2016-11-23 |
| AU2011306391A1 (en) | 2013-04-11 |
| CN103221049A (zh) | 2013-07-24 |
| ES2616752T3 (es) | 2017-06-14 |
| HK1187554A1 (zh) | 2014-04-11 |
| US9029369B2 (en) | 2015-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| DOP2013000104A (es) | Antagonistas de mdm2 de espiro-oxindol | |
| CU20150163A7 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| BR112012011317A2 (pt) | antagonistas espiro-oxindóis de mdm2 | |
| PE20150092A1 (es) | Composiciones farmaceuticas que contienen fumarato de dimetilo | |
| BR112012023021A2 (pt) | compostos de indazol e seus usos | |
| BR112015020389A8 (pt) | compostos carbazol úteis como inibidores de bromodomínio, seu uso, bem como composição e produto farmacêuticos compreendendo os mesmos | |
| CL2014001158A1 (es) | Compuestos derivados de piperazina alquilados; composicion farmaceutica que los comprende; proceso para preparar la composicion farmaceutica; kit y uso en el tratamiento de trastornos inmunes, cancer, enfermedades cardiovasculares, inflamacion, entre otros. | |
| CL2010001348A1 (es) | Compuestos derivados de 1-oxo-2,3-dihidro-1h-isoindolin-5-il)-isoxazol-3-carboxamida, potenciadores de los mglur2; composicion farmaceutica; y su uso para aliviar los sintomas o disminuir la aparicion de los sintomas de ezquizofrenia o ansiedad. | |
| EA201690223A1 (ru) | Ингибиторы фактора в комплемента на основе производных пиперидинилиндола и их применение | |
| EA201291310A1 (ru) | Композиция ингибитора jak для местного применения | |
| CR20190073A (es) | FORMAS DE DOSIFICACIÓN DE RUXOLITINIB DE LIBERACIÓN SOTENIDA (Divisional 2015-265) | |
| UY35040A (es) | Pirrolopirimidinilamino-benzotiazolonas sustituidas | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| SV2011003901A (es) | Compuestos de arilo con sustituyentes heterocíclicos como inhibidores de hif | |
| BR112013028534A2 (pt) | compostos tricíclicos parcialmente saturados e métodos para produção e utilização dos mesmos | |
| CO6640327A2 (es) | Compuestos de pirazol como inhibidores del receptor sigma | |
| CO2019008053A2 (es) | Agente terapéutico para enfermedades del hígado | |
| UY35276A (es) | Nuevos compuestos que inhiben la actividad de Lp-PLA2 | |
| ECSP15013883A (es) | Benzamidas | |
| AR083095A1 (es) | Cocristal de aprepitant l-prolina y composicion farmaceutica | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| CO6280488A2 (es) | Combinacion farmaceutica | |
| MX2016000294A (es) | Composicion farmaceutica para liberacion sostenida de lanreotida. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |